Results 21 to 30 of about 2,116 (170)

Tralokinumab in atopic dermatitis [PDF]

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2021
SummaryAtopic dermatitis (AD) is a common chronic inflammatory disease characterized by recurrent eczematous lesions and intense pruritus, and it can have marked negative impact on those affected. Pathophysiologically, AD is complex with genetic predisposition and environmental provocation being important contributors. Mechanistically these can promote
Andreas, Wollenberg, Stephan, Weidinger, Margitta, Worm, Thomas, Bieber   +3 more
openaire   +2 more sources

Tralokinumab Efficacy Over 1 Year in Adults with Moderate-to-Severe Atopic Dermatitis: Pooled Data from Two Phase III Trials [PDF]

, 2023
Two phase III trials, ECZTRA 1 and 2, confirmed the efficacy and safety of tralokinumab versus placebo in adults with moderate-to-severe atopic dermatitis (AD).
Eric L. Simpson, Katoh, Norito, Pink, Andrew E., Blauvelt, Andrew, Andreas Wollenberg, Andrew E. Pink, Margitta Worm, Simpson, Eric L., Wollenberg, Andreas, Pink, Andrew, April W. Armstrong, Melinda Gooderham, Ketty Peris, Armstrong, April, Ann-Marie Tindberg, Steffensen, Louise Abildgaard, Simpson, Eric, Worm, Margitta, Andrew Blauvelt, Norito Katoh, Mark, Thomas, Thomas Mark, Peris, Ketty, Gooderham, Melinda, Puig Sanz, Lluís, Sébastien Barbarot, Louise Abildgaard Steffensen, Barbarot, Sébastien, Armstrong, April W., Puig, Luis, Universitat Autònoma de Barcelona, Luis Puig, Tindberg, Ann-Marie   +32 more
core   +3 more sources

Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review

Clinical, Cosmetic and Investigational Dermatology
Giuseppe Lauletta,1 Luca Potestio,1 Cataldo Patruno,2 Mario De Lucia,1 Maddalena Napolitano1 1Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 2Department of Medicine and Health ...
Maddalena Napolitano, Luca Potestio
exaly   +2 more sources

Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab

Dermatology and Therapy, 2023
Introduction IL-13 is the primary upregulated cytokine in atopic dermatitis (AD) skin and is the pathogenic mediator driving AD pathophysiology. Lebrikizumab, tralokinumab and cendakimab are therapeutic monoclonal antibodies (mAb) that target IL-13 ...
Angela J. Okragly, Aya Ryuzoji, Isabella Wulur, Montanea Daniels, Robert D. Van Horn, Chetan N. Patel, Robert J. Benschop   +6 more
doaj   +1 more source

Mechanistic modeling of a human IgG4 monoclonal antibody (tralokinumab) Fab‐arm exchange with endogenous IgG4 in healthy volunteers

CPT: Pharmacometrics & Systems Pharmacology, 2022
Therapeutic IgG4 antibodies engage in Fab‐arm exchange with endogenous human immunoglobulin G4 (IgG4) to form monovalent hybrid molecules. A mechanistic population model was developed to quantitatively characterize the dynamic Fab‐arm exchange of ...
Bing Wang, Jo Goodman, Lorin K. Roskos
doaj   +1 more source

Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice [PDF]

, 2023
BACKGROUND: Evidence about tralokinumab treatment for moderate-to-severe atopic dermatitis (AD) in daily practice is limited. AIM: To report the first evidence, to our knowledge, from daily practice of treatment with tralokinumab in patients with AD ...
Shareef, Madena, Schlösser, Anne R., Nijsten, Tamar E.C., Olydam, Jill, Tamar E C Nijsten, Hijnen, Dirk Jan; id_orcid, Jill Olydam, Madena Shareef, Hijnen, Dirk Jan, Anne R Schlösser, Dirk Jan Hijnen   +10 more
core   +2 more sources

Selective IL-13 inhibitors for the treatment of atopic dermatitis

Drugs in Context, 2021
Background: Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases worldwide. AD pathogenesis is multifactorial, involving environmental and genetic factors.
Francisca Gonçalves, Egídio Freitas, Tiago Torres   +2 more
doaj   +1 more source

Tralokinumab bei atopischer Dermatitis [PDF]

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2021
ZusammenfassungAtopische Dermatitis (AD) ist eine häufige chronisch‐entzündliche Krankheit mit rezidivierenden ekzematösen Läsionen und starkem Pruritus. Sie kann erhebliche negative Auswirkungen auf die Betroffenen haben. Zur komplexen Pathophysiologie der AD tragen genetische Prädisposition und umweltbedingte Provokationen wesentlich bei ...
Andreas Wollenberg, Stephan Weidinger, Margitta Worm, Thomas Bieber   +3 more
openaire   +1 more source

Clinical trials of antibody drugs in the treatments of atopic dermatitis

Frontiers in Medicine, 2023
Atopic dermatitis (AD) is one of the most common, relapsing, chronic inflammatory skin disease, being regarded as a global health issue. Recent studies have shown that Th2 cell-mediated type 2 immunity plays a central role in AD.
Guihao Zhou, Yueyao Huang, Ming Chu
doaj   +1 more source

Long-Term, Site-Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72-Week Real-World Study. [PDF]

J Dermatol
Tralokinumab, an anti\u2010IL\u201013 antibody, is effective for atopic dermatitis (AD); however, its long\u2010term (>\u20091\u2009year) effectiveness specific to each anatomical site is unknown in real\u2010world settings.
Shiba M, Hagino T, Uchiyama A, Saeki H, Fujimoto E, Motegi SI, Kanda N.   +6 more
europepmc   +2 more sources